Literature DB >> 9098275

Outcomes of trabeculectomy for primary open-angle glaucoma.

K Nouri-Mahdavi, L Brigatti, M Weitzman, J Caprioli.   

Abstract

PURPOSE: To determine the long-term functional and structural outcomes in patients treated with trabeculectomy for primary open-angle glaucoma.
METHODS: Records of 78 consecutive patients (78 eyes) who had their first trabeculectomy were studied retrospectively (duration of follow-up, 25 to 112 months). Serial automated perimetry and stereoscopic optic disc photographs were used to assess the long-term efficacy of trabeculectomy to prevent progressive glaucomatous damage. Stereoscopic optic disc photographs were available for 29 eyes (38%). Criteria for intraocular pressure control were a minimum intraocular pressure reduction of 20% and intraocular pressure at or below 20 mmHg.
RESULTS: There was no evidence of progression of glaucomatous damage in 81% and 65% of the eyes after 3 and 6 years, respectively. The visual field deteriorated in 16 eyes (21%) and progressive structural optic nerve damage occurred in 4 eyes (5%) during follow-up. Deterioration of the optic nerve head in the absence of visual field progression was detected in three (4%) of those eyes. In 19 eyes (25%), further glaucoma surgery was performed. The probability of successful intraocular pressure control after a single operation was 48% and 40% at 3 and 5 years, respectively.
CONCLUSION: Progressive glaucomatous damage occurs in about one third of eyes with moderate to severe primary open-angle glaucoma over a 6-year follow-up after trabeculectomy.

Entities:  

Mesh:

Year:  1995        PMID: 9098275     DOI: 10.1016/s0161-6420(95)30796-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  31 in total

1.  Course of exfoliation and simplex glaucoma after primary trabeculectomy.

Authors:  V Popovic; J Sjöstrand
Journal:  Br J Ophthalmol       Date:  1999-03       Impact factor: 4.638

2.  Safe trabeculectomy technique: long term outcome.

Authors:  I Stalmans; A Gillis; A-S Lafaut; T Zeyen
Journal:  Br J Ophthalmol       Date:  2006-01       Impact factor: 4.638

3.  Non-penetrating deep sclerectomy without or with autologous scleral implant in open-angle glaucoma: medium-term results.

Authors:  Sylvie Devloo; Cathérine Deghislage; Lidwine Van Malderen; Marc Goethals; Thierry Zeyen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-07-08       Impact factor: 3.117

4.  Decorin and suramin inhibit ocular fibroblast collagen production.

Authors:  H Mietz; P Chévez-Barrios; M W Lieberman; M Wendt; R Gross; S F Basinger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-06       Impact factor: 3.117

5.  Medium to long-term intraocular pressure control following small flap trabeculectomy (microtrabeculectomy) in relatively low risk eyes.

Authors:  S A Vernon; C Gorman; H J Zambarakji
Journal:  Br J Ophthalmol       Date:  1998-12       Impact factor: 4.638

6.  Long-term results of trabeculectomy in eyes that were initially successful.

Authors:  J T Wilensky; T C Chen
Journal:  Trans Am Ophthalmol Soc       Date:  1996

7.  Minimally invasive combined glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent.

Authors:  Alessandra De Gregorio; Emilio Pedrotti; Luisa Russo; Simonetta Morselli
Journal:  Int Ophthalmol       Date:  2017-05-29       Impact factor: 2.031

8.  Subconjunctival bevacizumab as an adjuvant in first-time filtration surgery for patients with primary glaucomas.

Authors:  Luis Gustavo Biteli; Tiago Santos Prata
Journal:  Int Ophthalmol       Date:  2013-02-07       Impact factor: 2.031

9.  Potential role for angiotensin-converting enzyme inhibitors in the treatment of glaucoma.

Authors:  Kazuyuki Hirooka; Fumio Shiraga
Journal:  Clin Ophthalmol       Date:  2007-09

10.  Immune maintenance in glaucoma: boosting the body's own neuroprotective potential.

Authors:  Michal Schwartz; Anat London
Journal:  J Ocul Biol Dis Infor       Date:  2009-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.